WO1998046588A3 - Compounds and therapies for the prevention of vascular and non-vascular pathologies - Google Patents

Compounds and therapies for the prevention of vascular and non-vascular pathologies Download PDF

Info

Publication number
WO1998046588A3
WO1998046588A3 PCT/US1998/007063 US9807063W WO9846588A3 WO 1998046588 A3 WO1998046588 A3 WO 1998046588A3 US 9807063 W US9807063 W US 9807063W WO 9846588 A3 WO9846588 A3 WO 9846588A3
Authority
WO
WIPO (PCT)
Prior art keywords
vascular
compounds
tgf
beta
therapies
Prior art date
Application number
PCT/US1998/007063
Other languages
French (fr)
Other versions
WO1998046588A2 (en
Inventor
David J Grainger
James C Metcalfe
Sudhakar Kasina
Original Assignee
Neorx Corp
David J Grainger
James C Metcalfe
Sudhakar Kasina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp, David J Grainger, James C Metcalfe, Sudhakar Kasina filed Critical Neorx Corp
Priority to AU69598/98A priority Critical patent/AU6959898A/en
Publication of WO1998046588A2 publication Critical patent/WO1998046588A2/en
Publication of WO1998046588A3 publication Critical patent/WO1998046588A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/108Osteoporosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/323Arteriosclerosis, Stenosis

Abstract

The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.
PCT/US1998/007063 1997-04-11 1998-04-09 Compounds and therapies for the prevention of vascular and non-vascular pathologies WO1998046588A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69598/98A AU6959898A (en) 1997-04-11 1998-04-09 Compounds and therapies for the prevention of vascular and non-vascular pathol ogies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4385297P 1997-04-11 1997-04-11
US60/043,852 1997-04-11

Publications (2)

Publication Number Publication Date
WO1998046588A2 WO1998046588A2 (en) 1998-10-22
WO1998046588A3 true WO1998046588A3 (en) 1999-01-07

Family

ID=21929208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007063 WO1998046588A2 (en) 1997-04-11 1998-04-09 Compounds and therapies for the prevention of vascular and non-vascular pathologies

Country Status (3)

Country Link
US (5) US6117911A (en)
AU (1) AU6959898A (en)
WO (1) WO1998046588A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933270B2 (en) 2002-08-12 2015-01-13 The Brigham And Women's Hospital, Inc. Use of docasatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401911T1 (en) * 1993-05-13 2008-08-15 Poniard Pharmaceuticals Inc A VASCULAR SMOOTH MUSCLE CELL INHIBITOR FOR THERAPEUTIC USE
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
ATE377418T1 (en) * 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES WITH TAMOXIFEN ANALOGUES
ATE279916T1 (en) * 1996-07-22 2004-11-15 Renovo Ltd USE OF SUBSTANCES THAT PROMOTE THE ESTROGEN ACTION FOR THE TREATMENT OF WOUNDS
JP2001514663A (en) * 1997-03-12 2001-09-11 エスモンド,ロバート ダブリュー. Methods for treating or preventing Alzheimer's disease
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
ES2350454T3 (en) * 1998-11-27 2011-01-24 Ucb Pharma S.A. COMPOSITIONS AND METHODS TO INCREASE THE MINERALIZATION OF THE BONE SUBSTANCE.
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AR023819A1 (en) * 1999-05-03 2002-09-04 Astrazeneca Ab PHARMACEUTICAL FORMULATION, KIT OF PARTS AND USE OF THE FORMULATION
US6403637B1 (en) 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
EP1214077B1 (en) * 1999-09-21 2004-01-28 Institut de Cardiologie de Montreal Local delivery of 17-beta estradiol for improving vascular endothelium function after vascular injury
ATE344226T1 (en) 2000-02-16 2006-11-15 Brigham & Womens Hospital ASPIRIN-RELEASED LIPID MEDIATORS
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
BR0017324A (en) * 2000-08-24 2003-07-29 Lytone Enterprise Inc Improvement introduced in extended release combinations and compositions
US7104958B2 (en) * 2001-10-01 2006-09-12 New Health Sciences, Inc. Systems and methods for investigating intracranial pressure
AU2002211304A1 (en) * 2000-09-29 2002-04-08 New Health Sciences, Inc. Systems and methods for assessing vascular effects of a treatment
US6955648B2 (en) * 2000-09-29 2005-10-18 New Health Sciences, Inc. Precision brain blood flow assessment remotely in real time using nanotechnology ultrasound
EP1370210A4 (en) * 2001-02-07 2004-08-18 Mclean Hospital Corp Cholesterol-lowering agents as treatment for psychological and cognitive disorders
CA2438907A1 (en) * 2001-02-15 2002-09-06 King Pharmaceuticals, Inc. Manufacture of thyroid hormone tablets having consistent active moiety amounts
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP2004525109A (en) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド Stabilized thyroid hormone pharmaceutical composition and method for producing the same
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
PL395097A1 (en) * 2001-06-11 2011-10-10 Vertex Pharmaceuticals (Canada) Incorporated Process for the preparation of compound of the formula A constituting thiophene derivative
WO2003009807A2 (en) * 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
SE0102616D0 (en) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US7708712B2 (en) * 2001-09-04 2010-05-04 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in a body organ
US20050106138A1 (en) * 2001-09-18 2005-05-19 Hamid Rabb Specific depletion of cd4+ t cells
US20040044226A1 (en) * 2001-10-15 2004-03-04 Dininno Frank P. Estrogen receptor modulators
US20030165564A1 (en) * 2001-10-29 2003-09-04 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
KR20040068544A (en) * 2001-11-05 2004-07-31 더 브리검 앤드 우먼즈 하스피털, 인크. Soluble cd40l (cd154) as a prognostic marker of atherosclerotic diseases
DE60235775D1 (en) * 2001-11-08 2010-05-06 Ziscoat N V Intraluminal device with a therapeutic agent-containing coating
US6706756B1 (en) 2001-11-16 2004-03-16 University Of South Florida Vasodilating compound and method of use
AU2002365167A1 (en) 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
MX249034B (en) * 2002-05-28 2007-09-14 Dimensional Pharm Inc Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions.
AU2003249683A1 (en) * 2002-06-06 2003-12-22 Smithkline Beecham Corporation Nf-:b inhibitors
ATE449057T1 (en) * 2002-08-12 2009-12-15 Brigham & Womens Hospital RESOLVINE: BIOTEMPLATE FOR PERFORMING THERAPEUTIC APPLICATIONS
AU2003270909A1 (en) 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300091D0 (en) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (en) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
PL378566A1 (en) * 2003-03-14 2006-05-02 Celltech R & D, Inc. Ligands for tgf-beta binding proteins and uses thereof
CN1835974A (en) 2003-06-16 2006-09-20 细胞技术研究与发展公司 Antibodies specific for sclerostin and methods for increasing bone mineralization
EP1699527A1 (en) * 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US20050267197A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
US20050267091A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
FR2871061B1 (en) * 2004-06-04 2007-08-10 Coletica Sa ACTIVE PRINCIPLE CAPABLE OF INDUCING TRANSFORMATION FROM INACTIVE TGBF-LATENT TO ACTIVE TGFB
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8001922B2 (en) * 2004-09-28 2011-08-23 Atrium Medical Corporation Application of a coating on a medical device
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
WO2006037080A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Uv cured gel and method of making
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
KR101356335B1 (en) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 Omega-3 fatty acids and dyslipidemic agent for lipid therapy
WO2006062933A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
MX2007011031A (en) * 2005-03-08 2008-04-21 Reliant Pharmaceuticals Inc Treatment with statin and omega-3 fatty acids and a combination product thereof.
ITMI20050739A1 (en) * 2005-04-22 2006-10-23 Effebi Spa VALVE-ACTUATOR CONNECTION PLATE
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP5030947B2 (en) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド Compounds and methods for the treatment and prevention of flavivirus infections
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
JP2009511215A (en) 2005-10-15 2009-03-19 アトリウム メディカル コーポレーション Hydrophobic crosslinked gel for bioabsorbable drug carrier coating
AU2006308219B2 (en) * 2005-10-25 2010-06-10 Unilever Plc Food composition
JP2009515991A (en) 2005-11-18 2009-04-16 トラスティーズ オブ ボストン ユニバーシティ Treatment and prevention of bone loss using resolvin
JP2010508897A (en) 2006-11-06 2010-03-25 アトリウム メディカル コーポレーション Coated surgical mesh
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US8003685B2 (en) 2006-11-15 2011-08-23 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
GB0702871D0 (en) * 2007-02-14 2007-03-28 Tcp Innovations Ltd Improved compositions and combinations 1
US20080194527A1 (en) * 2007-02-14 2008-08-14 Tcp Innovations Ltd Compositions and combinations 2
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
CN101896201A (en) * 2007-12-14 2010-11-24 安进公司 Method for treating bone fracture with anti-sclerostin antibodies
GEP20125707B (en) * 2007-12-18 2012-12-10 Glenmark Pharmaceuticals Sa Chromane derivatives as trpv3 modulators
US20090163452A1 (en) * 2007-12-20 2009-06-25 Schwartz Janice B Compositions and methods for lowering serum cholesterol
EP2285794A4 (en) * 2008-06-17 2012-08-29 Glenmark Pharmaceuticals Sa Chromane derivatives as trpv3 modulators
CA2743491C (en) 2008-11-11 2016-10-11 Zelton Dave Sharp Inhibition of mammalian target of rapamycin
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20120252862A1 (en) * 2009-09-28 2012-10-04 Yeditepe Universites Dissolvable Film Strip Comprising Natural Components
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
GB2475907A (en) 2009-12-04 2011-06-08 Tcp Innovations Ltd Composition comprising a mixture of clopidogrel and droloxifene
US20110136858A1 (en) * 2009-12-04 2011-06-09 Grainger David J Preferred Combination Therapy
US20110184006A1 (en) * 2010-01-28 2011-07-28 National Research Council Of Sri Lanka Method and composition for thermally stabilizing vitamin c within nano layers of montmorillonite clay
US8465939B2 (en) * 2010-03-02 2013-06-18 Nox Technologies, Inc. Aging-related circulating particle-associated lipoprotein B oxidase (apoBNOX) and inhibitors thereof
US20110269849A1 (en) * 2010-05-03 2011-11-03 Yuan Yao Emulsions and Methods for the Preparation Thereof, and Methods for Improving Oxidative Stability of Lipids
RS56210B1 (en) 2010-05-14 2017-11-30 Amgen Inc High concentration antibody formulations
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
CN103517920B (en) 2011-03-25 2018-04-17 安进公司 Anti- hardened proteins (SCLEROSTIN) antibody crystals and its preparation
MX355816B (en) 2011-08-04 2018-05-02 Amgen Inc Method for treating bone gap defects.
IN2014CN04634A (en) 2011-12-28 2015-09-18 Amgen Inc
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
WO2014006100A1 (en) 2012-07-05 2014-01-09 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
DK2968281T3 (en) 2013-03-13 2020-11-02 Univ Texas MTOR INHIBITORS FOR PREVENTING THE GROWTH OF THE INTESTINAL POLYPH
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3724236A4 (en) * 2017-12-14 2021-07-21 Calroy Health Sciences, LLC Methods to stabilize and reverse atherosclerotic lesions by sulfated polysaccharides
SG11202008206TA (en) 2018-03-30 2020-09-29 Amgen Inc C-terminal antibody variants
WO2023177676A1 (en) * 2022-03-14 2023-09-21 University Of South Florida Genistein for asthma treatment

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3445473A (en) * 1965-04-10 1969-05-20 Hoechst Ag 3-anilino-thiophene-4-carboxylic acids,esters,and amides
FR2255063A1 (en) * 1973-12-24 1975-07-18 Bioindustria Spa Dialkyl 3,4-dihydroxy-2,5-thiophene dicarboxylates - antimycotics and antitrichomonals prepd from dioxalates and thiodiacetates
US4219656A (en) * 1978-10-24 1980-08-26 American Cyanamid Company 3,4-Disubstituted thiophenes
GB1587084A (en) * 1976-08-23 1981-03-25 Hoffmann La Roche Thiophene derivatives
US4282246A (en) * 1980-03-07 1981-08-04 Pfizer Inc. Antidiabetic furancarboxylic and thiphenecarboxylic acids
US4317915A (en) * 1976-08-23 1982-03-02 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4382143A (en) * 1979-07-23 1983-05-03 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs
US4428963A (en) * 1976-08-23 1984-01-31 Hoffmann-La Roche Inc. Novel thiophene derivatives
JPS5942375A (en) * 1982-09-03 1984-03-08 Mitsubishi Petrochem Co Ltd 4-hydroxy-2-thiopheneacetic acid derivative
US4767758A (en) * 1984-12-28 1988-08-30 Consiglio Nazionale Delle Ricerche Pharmaceutical compositions containing thiophene compounds, and new thiophene compounds
WO1992011895A1 (en) * 1990-12-28 1992-07-23 Boston Scientific Corporation Balloon drug delivery system
WO1992019612A1 (en) * 1991-04-24 1992-11-12 Medea Research S.R.L. Antiarteriosclerotic agent, a process for the preparation thereof and the use thereof
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
EP0675103A2 (en) * 1994-03-01 1995-10-04 Scotia Holdings Plc Derivatives of essential fatty acids and nonsteroidal antiinflammatory drugs
WO1996007402A1 (en) * 1994-09-07 1996-03-14 Orion-Yhtymä Oy Triphenylethylenes for the prevention and treatment of osteoporosis
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US528040A (en) * 1894-10-23 Telephone circuit and signal
GB1015787A (en) 1962-08-03 1966-01-05 Giuseppe Carlo Sigurta Tris-(p-methoxyphenyl)ethylene derivatives
US3634517A (en) * 1968-08-19 1972-01-11 Richardson Merrell Inc Triarylalkenones
US6306846B1 (en) * 1972-05-31 2001-10-23 John R. J. Sorenson Anti-inflammatory and anti-ulcer compounds and process
US4221785A (en) 1978-05-30 1980-09-09 Sorenson John R J Anti-inflammatory and anti-ulcer compounds and process
US5082834A (en) 1978-05-30 1992-01-21 Sorensen John R J Anti-inflammatory and anti-ulcer compounds and process
US5521171A (en) 1975-03-31 1996-05-28 Sorenson; John R. J. Anti-inflammatory and anti-ulcer compounds and process
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4323707A (en) * 1975-10-28 1982-04-06 Eli Lilly And Company Antifertility compounds
JPS6012381B2 (en) 1976-10-06 1985-04-01 久光製薬株式会社 thermal compress
DE2861560D1 (en) 1977-11-28 1982-03-04 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
DE2817157A1 (en) * 1978-04-17 1979-10-25 Schering Ag USE OF ANTIOESTROGEN AND ANTIGONADOTROP ACTING ANTIANDROGEN FOR PROPHYLAXIS AND THERAPY OF PROSTATE HYPERPLASIA
US4440754A (en) 1978-05-30 1984-04-03 Sorenson John R J Anti-inflammatory and anti-ulcer compounds and process
US4239778A (en) * 1978-09-12 1980-12-16 The University Of Illinois Foundation Azaprostanoic acid analogs and their use as inhibitors of platelet aggregation
US4315028A (en) 1978-12-22 1982-02-09 Scheinberg Israel H Method of treatment of rheumatoid arthritis
ATE1418T1 (en) * 1979-05-15 1982-08-15 Imperial Chemical Industries Plc 1-HYDROCARBYLOXYPHENYL-1.2-DIPHENYLALKE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
AU532174B2 (en) 1979-08-15 1983-09-22 Stephen James Beveridge Copper chelate compounds
US4487780A (en) 1979-09-18 1984-12-11 Scheinberg Israel H Method of treatment of rheumatoid arthritis
US5658951A (en) * 1980-03-07 1997-08-19 Research Corporation Technologies Diphenylcyclopropyl analogs
US4879315A (en) * 1982-03-30 1989-11-07 The Board Of Regents For The University Of Oklahoma Cyclopropyl analogs as anti-estrogenic, anti-tumor and female fertility agents
US5658927A (en) * 1980-03-07 1997-08-19 Research Corporation Technologies Diphenylcyclopropyl analogs
US5098903A (en) * 1980-03-07 1992-03-24 Board Of Regents Of The University Of Oklahoma Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
EP0038867B1 (en) 1980-04-29 1983-09-28 Blendax-Werke R. Schneider GmbH & Co. Toothpaste
EP0038868B1 (en) 1980-04-29 1983-09-28 Blendax-Werke R. Schneider GmbH & Co. Toothpaste
US4442119A (en) * 1980-07-07 1984-04-10 The Board Of Regents For The University Of Oklahoma Cyclopropyl analogs as estrogenic and anti-fertility agents
DE3046719C2 (en) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-ene derivatives, processes for their preparation and pharmaceuticals
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4670428A (en) 1982-02-01 1987-06-02 International Copper Research Association, Inc. Method for treating convulsions and epilepsy with organic copper compounds
US5015666A (en) * 1982-03-30 1991-05-14 Board of Reagents of the University of Oklahoma Triarylcyclopropanes as antiestrogens and antitumor agents
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
FI77839C (en) * 1982-05-27 1989-05-10 Farmos Oy FOERFARANDE FOER FRAMSTAELLNING AV NYA THERAPEUTIC EFFECTIVE TRIPHENYLALKAN- OCH ALKENDERIVAT.
US4657928A (en) 1982-05-27 1987-04-14 International Copper Research Association, Inc. Organic copper complexes as radioprotectants
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5705477A (en) 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US5656587A (en) 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US4491574A (en) 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
US4629694A (en) 1983-07-12 1986-12-16 Cornell Research Foundation, Inc. Detecting and distinguishing between plasminogen activators
IT1198654B (en) * 1983-07-26 1988-12-21 Edoardo Furia AUTOMATIC MACHINE FOR ESTEMPORANEA MANUFACTURE AND DISTRIBUTION OF SORBET ICE AND OTHER
EP0170063B1 (en) 1984-07-31 1988-08-24 Mitsubishi Petrochemical Co., Ltd. Copper-type conductive coating composition
US4757059A (en) 1984-08-14 1988-07-12 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
US4758555A (en) * 1984-08-14 1988-07-19 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
US4758554A (en) 1984-08-14 1988-07-19 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
US4760051A (en) 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5470876A (en) 1985-07-18 1995-11-28 Proctor; Peter H. Topical sod for treating hair loss
DE3532860C1 (en) 1985-09-14 1987-03-12 Blendax Werke Schneider Co Oral hygiene products
US4853377A (en) 1985-10-15 1989-08-01 Pollack Robert L Method and composition for increasing production of serotonin
US5120535A (en) 1986-11-26 1992-06-09 Oncogen Oncostatin M and novel compositions having anti-neoplastic activity
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
EP0260066B1 (en) * 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
HU199281B (en) 1986-10-17 1990-02-28 Biogal Gyogyszergyar Synergetic unsenziting face- and body-cosmetics
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
DE3781546D1 (en) * 1987-04-21 1992-10-08 Heumann Pharma Gmbh & Co STABLE SOLVENT ADDUCTS OF Z-1- (P-BETA-DIMETHYLAMINO-ETHOXYPHENYL) -1- (P-HYDROXYPHENYL) -2-PHENYLBUT-1-EN.
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
SE8702254D0 (en) 1987-05-29 1987-05-29 Kabivitrum Ab NOVEL HEPARIN DERIVATIVES
US5221620A (en) 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
DE3737340A1 (en) 1987-11-04 1989-05-24 Bayer Ag NEW FLUORMETHOXYPHENYL DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US4956188A (en) 1988-10-20 1990-09-11 Zinpro Corporation Copper complexes with alpha hydroxy organic acids and their use as nutritional supplements
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
CA2002011A1 (en) 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
CA2005120A1 (en) 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
US5304541A (en) 1988-12-15 1994-04-19 Bristol-Myers Squibb Company Methods using novel chimeric transforming growth factor-β1/β2
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US4948594A (en) * 1989-01-03 1990-08-14 Zinpro Corporation Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements
US4900561A (en) 1989-01-03 1990-02-13 Zinpro Corporation Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements
US5356630A (en) 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5100885A (en) 1989-08-01 1992-03-31 Johnson Matthey, Inc. Copper radiosensitizers
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US5023237A (en) 1989-08-30 1991-06-11 Procyte Corporation Methods and compositions for healing ulcers
US5145838A (en) 1989-08-30 1992-09-08 Procyte Corporation Methods and compositions for healing ulcers
US5158934A (en) * 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
IL95500A (en) 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
US5126348A (en) 1989-09-26 1992-06-30 The University Of Colorado Foundation, Inc. Bioavailability enhancers
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
AU634871B2 (en) 1990-03-20 1993-03-04 Banyu Pharmaceutical Co., Ltd. Substituted amine derivatives having anti-hyperlipemia activity
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5824647A (en) 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5332576A (en) 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JPH04312526A (en) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd Remedy for osteopathy
US5229495A (en) 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5216126A (en) 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
JP3446214B2 (en) 1991-06-21 2003-09-16 ライオン株式会社 Liquid transparent oral composition
US5126021A (en) * 1991-07-17 1992-06-30 Applied Biosystems Inc. Low-viscosity polymer solution for capillary electrophoresis
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU2738392A (en) 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
JPH05255084A (en) * 1992-01-17 1993-10-05 Dai Ichi Seiyaku Co Ltd Agent for suppressing restenosis after percutaneous transluminal coronary angioplasty
US5280109A (en) 1992-01-27 1994-01-18 Ludwig Institute For Cancer Research Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
US5444164A (en) 1992-02-05 1995-08-22 Bristol-Myers Squibb Company TGF-β induced gene
AU3920693A (en) 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
ES2125342T3 (en) * 1992-07-30 1999-03-01 Cal Int Ltd ESTERS AND COMBINATIONS OF AN ORGANIC NITRATE AND A SALICILATE.
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
AU669256B2 (en) 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
GB2273873A (en) 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
US5420243A (en) 1993-01-26 1995-05-30 Celtrix Pharmaceuticals, Inc. Biologically active TGF-β2 peptides
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5451603A (en) * 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
WO1994026303A1 (en) 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5409955A (en) 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
IL109990A (en) * 1993-06-21 1999-06-20 Lilly Co Eli Materials and methods for screening anti-osteoporosis agents
DE4320896A1 (en) 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Product for the therapy and prophylaxis of dementias
DE4320898A1 (en) 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Product for the therapy and prophylaxis of disorders occurring in cases of plasma lipid imbalance
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
TW303299B (en) * 1993-07-22 1997-04-21 Lilly Co Eli
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
EP0711158B2 (en) 1993-07-29 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5418252A (en) * 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5480904A (en) * 1993-10-28 1996-01-02 Eli Lilly And Company Methods for inhibiting uterine fibrosis
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5389670A (en) * 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5462949A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of inhibiting fertility in women
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5461064A (en) * 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5446053A (en) * 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5451589A (en) * 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5451590A (en) * 1993-12-21 1995-09-19 Eli Lilly & Co. Methods of inhibiting sexual precocity
US5439931A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5439923A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method of inhibiting seborrhea and acne
US5591753A (en) * 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
AU1670995A (en) * 1994-01-28 1995-08-15 Cal International Limited A pharmaceutical product comprising a salicylate of an esterifiable ace-inhibitor
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5451414A (en) 1994-03-15 1995-09-19 Heritage Environmental Services, Inc. Micronutrient supplement
CA2145614A1 (en) 1994-03-31 1995-10-01 Jeffrey A. Dodge Intermediates and processes for preparing benzothiophene compounds
SE9401174D0 (en) * 1994-04-07 1994-04-07 Astra Ab New combination
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5656450A (en) 1994-05-27 1997-08-12 Board Of Regents, The University Of Texas System Activation of latent transforming growth factor β by matrix vesicles
JPH07316192A (en) 1994-05-27 1995-12-05 Hoechst Japan Ltd L-lysyl-glycyl-l-histidine and therapeutic agent for wound
US5466810A (en) * 1994-06-10 1995-11-14 Eli Lilly And Company 2-amino-3-aroyl-benzo[β]thiophenes and methods for preparing and using same to produce 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)-benzoyl]benzo[β]thiophenes
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
CA2195474A1 (en) * 1994-07-20 1996-02-01 Cedo Martin Bagi Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US5491159A (en) * 1994-08-30 1996-02-13 American Home Products Corporation 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-oxazoles as anti-atherosclerotic agents
US5731436A (en) 1994-08-31 1998-03-24 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5660873A (en) 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
US5571808A (en) * 1995-01-31 1996-11-05 Eli Lilly And Company Method for treating smoking-related bone loss
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US5563054A (en) * 1995-03-31 1996-10-08 Eli Lilly And Company Process for preparation of benzo[B]thiophene glucuronides
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
US5912006A (en) 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5865766A (en) * 1997-01-10 1999-02-02 Emory University Multichannel, multipurpose sample collection and drug delivery system for laboratory animals
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
CA2461812C (en) * 2001-09-27 2011-09-20 Allergan, Inc. 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US7005444B2 (en) * 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3445473A (en) * 1965-04-10 1969-05-20 Hoechst Ag 3-anilino-thiophene-4-carboxylic acids,esters,and amides
FR2255063A1 (en) * 1973-12-24 1975-07-18 Bioindustria Spa Dialkyl 3,4-dihydroxy-2,5-thiophene dicarboxylates - antimycotics and antitrichomonals prepd from dioxalates and thiodiacetates
GB1587084A (en) * 1976-08-23 1981-03-25 Hoffmann La Roche Thiophene derivatives
US4317915A (en) * 1976-08-23 1982-03-02 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4428963A (en) * 1976-08-23 1984-01-31 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4219656A (en) * 1978-10-24 1980-08-26 American Cyanamid Company 3,4-Disubstituted thiophenes
US4382143A (en) * 1979-07-23 1983-05-03 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs
US4282246A (en) * 1980-03-07 1981-08-04 Pfizer Inc. Antidiabetic furancarboxylic and thiphenecarboxylic acids
JPS5942375A (en) * 1982-09-03 1984-03-08 Mitsubishi Petrochem Co Ltd 4-hydroxy-2-thiopheneacetic acid derivative
US4767758A (en) * 1984-12-28 1988-08-30 Consiglio Nazionale Delle Ricerche Pharmaceutical compositions containing thiophene compounds, and new thiophene compounds
WO1992011895A1 (en) * 1990-12-28 1992-07-23 Boston Scientific Corporation Balloon drug delivery system
WO1992019612A1 (en) * 1991-04-24 1992-11-12 Medea Research S.R.L. Antiarteriosclerotic agent, a process for the preparation thereof and the use thereof
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
EP0675103A2 (en) * 1994-03-01 1995-10-04 Scotia Holdings Plc Derivatives of essential fatty acids and nonsteroidal antiinflammatory drugs
WO1996007402A1 (en) * 1994-09-07 1996-03-14 Orion-Yhtymä Oy Triphenylethylenes for the prevention and treatment of osteoporosis
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 8416, Derwent World Patents Index; Class B03, AN 84-097443, XP002072406 *
FOYE, WILLIAM O. ET AL: "Heterocyclic analogs of salicyclic acid", CHIM. THER. (1967), 2(6), 462-6 CODEN: CHTPBA, XP002072404 *
GRAINGER, DAVID J. ET AL: "The serum concentration of active transforming growth factor-.beta. is severely depressed in advanced atherosclerosis", NAT. MED. (N. Y.) (1995), 1(1), 74-9 CODEN: NAMEFI;ISSN: 1078-8956, XP002072405 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933270B2 (en) 2002-08-12 2015-01-13 The Brigham And Women's Hospital, Inc. Use of docasatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma

Also Published As

Publication number Publication date
WO1998046588A2 (en) 1998-10-22
US6734208B2 (en) 2004-05-11
US6410587B1 (en) 2002-06-25
US20030064970A1 (en) 2003-04-03
US20060084696A1 (en) 2006-04-20
US7511070B2 (en) 2009-03-31
US7084171B2 (en) 2006-08-01
US20050020667A1 (en) 2005-01-27
US6117911A (en) 2000-09-12
AU6959898A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
WO1998046588A3 (en) Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP1616563A3 (en) Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases
MX9606386A (en) Agents affecting thrombosis hemostasis.
TR200100824T2 (en) Benzothiepines with activity as inhibitors of bile acid transport and taurocholate uptake in ileum
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2001015676A3 (en) Compositions and methods for modulating hdl cholesterol and triglyceride levels
WO1999043654A3 (en) Inhibitors of phospholipase enzymes
EP2138170A3 (en) Prevention and Treatment of Oxidative Stress Disorders by compounds which elevate intracellular levels of glutathione or Phase II Detoxification Enzymes
EA200300027A1 (en) METHOD OF TREATING CARDIOVASCULAR DISEASES
BR9811099A (en) Urokinase inhibitors
WO2002058734A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
WO2000061069A3 (en) Methods and compositions for use in the treatment of hyperlipidemia
WO2000013702A3 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
MXPA02010316A (en) Compositions and therapies for hyperlipidaemia associated disorders.
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
EP1099442A3 (en) Methods of administering apo B-secretion/MTP inhibitors
WO2001034132A3 (en) Use of an aldosterone antagonist for treating restenosis
EP1080724A4 (en) Mtp activity-lowering compositions
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2000071716A3 (en) Vascular endothelial growth factor dimers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998544032

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA